HC Wainwright upgraded shares of Sana Biotechnology (NASDAQ:SANA – Free Report) from a neutral rating to a buy rating in a report published on Tuesday morning, Marketbeat.com reports. They currently have $12.00 price objective on the stock. HC Wainwright also issued estimates for Sana Biotechnology’s FY2027 earnings at ($0.80) EPS and FY2028 earnings at ($0.64) […]